---
title: Prognostic Biomarkers in Evolving Melanoma Immunotherapy
date: '2024-12-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39707058/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241221170703&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Melanoma, a highly aggressive form of skin cancer, has seen significant
  advancements in treatment through the introduction of immunotherapy. However, the
  variability in patient responses underscores the need for reliable biomarkers to
  guide treatment decisions. This article reviews key biomarkers in melanoma immunotherapy,
  such as PD-L1 expression, tumor mutational burden (TMB), and gene expression profiles
  (GEPs). It also explores emerging biomarkers, including LAG-3 expression, immune
  ...
disable_comments: true
---
Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment through the introduction of immunotherapy. However, the variability in patient responses underscores the need for reliable biomarkers to guide treatment decisions. This article reviews key biomarkers in melanoma immunotherapy, such as PD-L1 expression, tumor mutational burden (TMB), and gene expression profiles (GEPs). It also explores emerging biomarkers, including LAG-3 expression, immune ...